NEW YORK, June 30, 2017 /PRNewswire/ --To Acquire Sinovac Biotech (Nasnaq: SVA) Sinobioway Consortium Raises Its Purchase Price To $8 Per Share.
On the evening
Just over 24 hours after the announcement above, Sinobioway Consortium ("Consortium B") rapidly submitted to Sinovac's Board of Director and the Special Committee a "Restate Offer" and raised the consideration for privatized acquisition to $8 per share, which is 14.3% higher than the consideration offered in the "Amalgamation Agreement."
(To find more information, please see Consortium B's announcement http://www.cninfo.com.cn/finalpage/2017-06-28/1203656646.PDF)
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/update-to-acquire-sinovac-biotech-nasnaq-sva-sinobioway-consortium-raises-its-purchase-price-to-8-per-share-300482679.html
SOURCE Shandong Sinobioway Biomedicine Co., Ltd
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All